Membranous nephropathy is treated with different drugs according to the severity of the disease, and renin-angiotensin-aldosterone receptor antagonists (valsartan, benadryl), glucocorticosteroids (prednisone acetate), immunosuppressants (tacrolimus, cyclophosphamide), rituximab, etc., are often chosen in clinical practice. For young patients without manifestation of nephrotic syndrome, without risk factors, and with normal renal function, immunosuppressants (cyclophosphamide) are not recommended, and renin-angiotensin-aldosterone receptor antagonists (Benadryl, valsartan) can be given to control blood pressure and provide long-term follow-up of renal function and urinary protein. Glucocorticoids (prednisone acetate), immunosuppressants, and rituximab are considered only in patients who present with nephrotic syndrome and have at least one of the following conditions. 1. urinary protein persistently exceeding 4 g/d after an observation period of at least 6 months of antihypertensive and protein-lowering and maintained at more than 50% of the baseline level with no downward trend. 2. Presence of severe, disabling or life-threatening clinical symptoms associated with nephrotic syndrome. 3. an increase in serum creatinine of ≥30% within 6 to 12 months of diagnosis, but eGFR of not less than 25-30 ml/(min1.73m²), and the above changes are not due to complications of nephrotic syndrome. 4. Avoidance of immunosuppressants is recommended in patients with persistent Scr >309.4 μmol/L and significant reduction in kidney volume, or in patients with concurrent severe or potentially life-threatening infections. Patients with membranous nephropathy are recommended to consult a regular hospital in time and follow the doctor’s instructions for standardized treatment.